UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. _______)*
|
Protalix BioTherapeutics Inc |
|
(Name of Issuer) |
|
|
|
Common Stock |
|
(Title of Class of Securities) |
|
|
|
74365A309 |
|
(CUSIP Number) |
|
|
|
12/04/2020 |
|
(Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[_] Rule 13d-1(b)
[_] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a current valid OMB control number.
|
CUSIP No. 74365A309 |
13G |
Page of |
|
|
|
|
1 |
NAME OF REPORTING PERSONS |
|
|
|
|
|
|
|
|
Burrage Capital Management |
|
2 |
CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP |
|
|
(a) ☐ |
|
|
(b) ☐
|
|
3 |
SEC USE ONLY |
|
|
|
|
|
|
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
|
|
|
United States of America |
|
|
5 |
SOLE VOTING POWER |
|
|
|
|
|
|
|
2,470,332 |
|
NUMBER OF |
6 |
SHARED VOTING POWER |
|
SHARES |
|
|
|
BENEFICIALLY |
|
0 |
|
OWNED BY |
7 |
SOLE DISPOSITIVE POWER |
|
EACH REPORTING |
|
|
|
PERSON WITH |
|
2,470,332 |
|
|
8 |
SHARED DISPOSITIVE POWER |
|
|
|
|
|
|
|
0 |
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
|
|
2,470,332 |
|
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
|
|
☐ |
|
|
|
|
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
|
|
|
|
|
7.41% (based upon 33,336,709 Shares) |
|
12 |
TYPE OF REPORTING PERSON |
|
|
|
Limited Liability Company (OO)
Item 1. Security and Issuer.
|
|
(a) |
Name of Issuer: Protalix BioTherapeutics Inc |
|
|
|
|
|
|
|
|
|
(b) |
Address of Issuer: 2 Snunit Street, Science Park PO Box 455, Carmiel, 20100, Israel |
|
|
|
|
|
|
|
|
|
|
|
|
Item 2. Identity and Background.
|
Item 2(a). |
Name of Person Filing: Burrage Capital Management LLC |
|
|
|
|
|
|
|
|
|
|
Item 2(b) |
Address of Principal Business Office or, if none, Residence: 314 Commonwealth Ave, #4, Boston, MA 02115 |
|
|
|
|
|
|
|
|
|
|
Item 2(c). |
Citizenship or Place of Organization: Delaware |
|
|
|
|
|
|
|
|
|
|
Item 2(d). |
Title of Class of Securities: Common Stock |
|
|
|
|
|
|
|
|
|
|
Item 2(e). |
CUSIP Number: 74365A309 |
|
|
|
|
|
|
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
|
(a) |
☐ |
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
|
|
|
|
|
|
|
(b) |
☐ |
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
|
|
|
|
|
|
|
(c) |
☐ |
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). |
|
|
|
|
|
|
|
(d) |
☐ |
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
|
|
|
|
|
|
|
(e) |
X |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
|
|
|
|
|
|
|
(f) |
☐ |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
|
|
|
|
|
|
|
(g) |
☐ |
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); |
|
|
|
|
|
|
|
(h) |
☐ |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
|
|
|
|
|
|
|
(i) |
☐ |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
|
|
|
|
|
|
|
(j) |
☐ |
Group, in accordance with §240.13d-1(b)(1)(ii)(J). |
Item 4. Ownership.
|
a) |
Amount beneficially owned: 2,470,332 |
|
b) |
Percent of class: 7.41% |
|
c) |
Number of shares as to which the Reporting Person has: |
|
|
|
|
|
(i) Sole power to vote or to direct the vote: 2,470,332 |
|
|
|
|
|
(ii) Shared power to vote or to direct the vote: 0 |
|
|
|
|
|
(iii) Sole power to dispose or to direct the disposition of: 2,470,332 |
|
|
|
|
|
(iv) Shared power to dispose or to direct the disposition of: 0 |
|
Item 5. |
Ownership of 5 Percent or Less of a Class. |
|
|
|
|
|
|
|
Item 6. |
Ownership of More than 5 Percent on Behalf of Another Person. |
|
|
|
|
|
|
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
|
|
|
|
|
|
|
Item 8. |
Identification and Classification of Members of the Group. |
|
|
|
|
|
|
|
Item 9. |
Notice of Dissolution of Group. |
|
|
|
|
|
|
Item 10. |
Certifications. |
For Rule 13d-1(b):
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
For Rule 13d-1(c)
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate.
|
|
|
|
|
|
|
|
|
|
|
Date: February 12, 2021 |
By: |
/s/ Jeff Crispen |
|
|
|
|
Jeff Crispen, CFO/COO |
|
|
|
|
|
|